TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05277051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381562
Description: GSK4381562 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381562
Description: GSK4381562 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381562
Description: GSK4381562 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4381562
Description: GSK4381562 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study: NCT05016583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paula Method
Description: 12 weeks of Paula Method of Exercises
Study: NCT06324929

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Participants complete a 35-minute survey to characterize demographics, parity, literacy, AEP risk, drinking levels, knowledge of FASD, location, Tribal affiliation, cultural preferences for tailoring, preferred digital platforms, methods of access to mobile devices/Internet, and interest in a digital women's health study about alcohol and birth control.
Study: NCT04983563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphy, eTact
Description: Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy.
Study: NCT05277051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belrestotug
Description: Belrestotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelistotug
Description: Nelistotug will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5764227
Description: GSK5764227 will be administered.
Study: NCT06523075

Intervention type: OTHER
Intervention: Tumor Necrosis Factor
Description: This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Tumor Necrosis Factor
Description: This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-1β
Description: This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-1β
Description: This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-12
Description: This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-12
Description: This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-18
Description: This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Interleukin-18
Description: This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Complement C3
Description: This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Complement C3
Description: This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.
Study: NCT05644041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravesically at a dose of 2000 mg.
Study: NCT04940780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Touch Therapies
Description: Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Touch Therapies
Description: Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
Study: NCT04834310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin
Description: All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All patients will receive an intraoperative dose of IV Cefazolin 2 g (re-dose after 4 hours) or IV Clindamycin 600mg (re-dose after 6 hours) for penicillin allergic patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: The experimental group will receive a postoperative 5-day course of Cephalexin 500 mg QID or Clindamycin 300 mg QID for penicillin allergic patients. All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a postoperative 5-day course of placebos (sugar capsules). All capsules will be encapsulated with size 00 dark-colored capsules compounded by the UCLA Investigational Pharmacy.
Study: NCT05217238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the rocuronium injection
Study: NCT06523075

Intervention type: OTHER
Intervention: Complement C5
Description: This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.

Intervention type: OTHER
Intervention: Complement C5
Description: This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.
Study: NCT05217238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the rocuronium injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the rocuronium injection
Study: NCT05840484

Intervention type: OTHER
Intervention: Active Surveillance
Description: Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.

Intervention type: OTHER
Intervention: Active Surveillance
Description: Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.

Intervention type: OTHER
Intervention: Active Surveillance
Description: Participants will be asked to complete questionnaires, have physical and rectal examinations, have prostate biopsies, and have imaging scans (such as MRIs). These visits will be done between every 6 months and every 2-3 years, depending on the test/procedure.
Study: NCT05277675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
Description: Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA will be performed in a percutaneous way guided contrast enhanced ultrasound.
Study: NCT05908032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study: NCT06492798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: umbilical cord mesenchymal stem cell
Description: intravenous infusion of umbilical cord mesenchymal stem cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: intravenous infusion of umbilical cord mesenchymal stem cell
Study: NCT05084417

Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.

Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.

Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.

Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.
Study: NCT05908032

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05084417

Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.
Study: NCT05470114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupixent®
Description: Dupixent® is an antibody given by subcutaneous injection.
Study: NCT05873816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProtEmbo - Cerebral Embolic Protection
Description: Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel - Cerebral Embolic Protection
Description: Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
Study: NCT05965180

Intervention type: DEVICE
Intervention: Fine Needle Photoacoustic Probe
Description: Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction
Study: NCT05385991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Description: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
Study: NCT06016530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: During a sleep deprivation period lasting over 36 hours, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant while adhering to a standardized diet. To achieve this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Supplementation
Description: Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
Study: NCT04803110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant placement after tooth extraction
Description: Immediate implant placement after partial or complete tooth extraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement after tooth extraction
Description: Immediate implant placement after partial or complete tooth extraction.
Study: NCT05323123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Exposure Prophylaxis (PrEP)
Description: FDA-approved oral medication to reduce the risk of HIV infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis (PrEP)
Description: FDA-approved oral medication to reduce the risk of HIV infection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARK
Description: SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK
Description: SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMpowerment
Description: PrEP adherence support app that utilizes engaging social networking and game-based elements, with an in-app portal for individualized live adherence counseling.
Study: NCT05725291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-116
Description: Administered intravenously
Study: NCT06647797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE Clinical Communication Campaign
Description: * Patient-facing educational materials~* Provider counseling training and job aid
Study: NCT06123143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized/structured CPAP weaning protocol
Description: Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
Study: NCT06401421

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA MRD test
Description: Blood and tissue samples will be collected for the ctDNA MRD test
Study: NCT05970822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402
Description: Escalating of BC3402 will be administered IV(intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered daily
Study: NCT04922151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 601
Description: intravitreal recombinant humanized anti-VEGF monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal recombinant humanized anti-VEGF monoclonal antibody
Study: NCT05639179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCAR-T Cells
Description: UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion.
Study: NCT06038955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality Based Cognitive Remediation
Description: The main component of the intervention is a virtual reality training platform in 360° Oculus Quest 2-software in which participants train their cognitive abilities guided by the therapist. The platform includes four immersive daily-life scenarios in which patients have consistently reported that they often experience cognitive difficulties: (1) a kitchen scenario focusing on planning and cooking a meal, (2) a supermarket scenario focusing on grocery shopping, (3) a restaurant scenario focusing on remembering names and personal information and (4) an office scenario focusing on planning, initiating, and completing work assignments. The virtual reality training is supported by a psychoeducation program that focuses on application of learned cognitive strategies in daily life.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual reality control training
Description: The virtual reality control training involves completing different virtual reality games that are available through the Oculus Quest games store.The chosen games involve no direct training of cognitive abilities such as planning skills og strategic learning, but merely involves simple reaction time and interaction with an entertaining environment that is meaningful to the participant and gives the impression of training cognitive skills.
Study: NCT05765279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray 1
Description: HH-120 nasal spray 5 times daily for 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray 2
Description: HH-120 nasal spray 8 times daily for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator 1
Description: Placebo nasal spray 5 times daily for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator 2
Description: Placebo nasal spray 8 times daily for 3 consecutive days
Study: NCT06141122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A recipe booklet
Description: A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
Study: NCT06010693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
Study: NCT06066437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: 177Lu rhPSMA-10.1
Description: Participants will receive 177Lu rhPSMA-10.1 alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Description: Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
Study: NCT06281496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AlloCare
Description: Survivorship supportive care
Study: NCT05385991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Description: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Description: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Description: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
Study: NCT05968768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
Study: NCT04384263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.